PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 25, 2026Scientific ReportsOpen Access

Blood parameters and whole-blood transcriptomics associated with immune-related adverse events in metastatic renal cell carcinoma during nivolumab plus ipilimumab

View Full Paper
Ask AI
Bookmark
Share

Authors

SKSatoka KinaseYNYoshiyuki NagumoBIBunpei Isoda

Discussion

Loading...

Member takes

Overview

Randomized trial identifies immune profiles predicting adverse events in metastatic renal cell carcinoma, suggesting personalized management strategies.

Key Points

  • The study aims to identify blood parameters and immune profiles associated with immune-related adverse events in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
  • Cohort study of n=51 patients with metastatic renal cell carcinoma
  • Analyzed pretreatment peripheral blood parameters and whole-blood transcriptomic profiles
  • Performed gene set enrichment analysis and CIBERSORTx evaluations to characterize immune profiles.
  • Higher lymphocyte (OR 14.36) and monocyte counts (OR 9.90) were linked to increased irAE risk.
  • Higher neutrophil counts (OR 0.08) and C-reactive protein levels (OR 0.27) correlated with decreased irAE risk.
  • Transcriptomic analysis showed upregulation of lymphocyte pathways and downregulation of neutrophil pathways in irAE patients.

Cite This Study

Kinase et al. (2026) studied this question.

synapsesocial.com/papers/69ec5aa788ba6daa22dac37bhttps://doi.org/10.1038/s41598-026-46960-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinoma2026
  2. 2Innate and adaptive immune features associated with immune-related adverse events2025 · 16 citations
  3. 3Abstract 2533: In-depth multi-omic profiling of immune cells in cancer patients developing immune-related adverse events2024
  4. 4Genome-wide association to identify SNPs associated with severe adverse events and clinical outcomes in advanced renal cell carcinoma treated with nivolumab.2026
  5. 559 Risk Factors of Immune Related Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors2024 · 2 citations